Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care

EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies

Now Viewing

EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies

EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies

EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What do partnerships look like between academic and community settings with regard to bispecifics?

What role do academic centers play in supporting community practices with bispecific therapy protocols?

Related Videos

Related Content

Advertisement

May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 16th 2025

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

Brooke McCormick

Facility-level disparities in adopting minimally invasive interval debulking surgery for ovarian cancer highlight urgent needs for equitable care access.

May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.

Related Content

Advertisement

May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 16th 2025

Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility

Brooke McCormick

Facility-level disparities in adopting minimally invasive interval debulking surgery for ovarian cancer highlight urgent needs for equitable care access.

May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.